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Abstract 
The importance of an early diagnosis and appropriate management of patients with primary 
aldosteronism (PA) has become increasingly clear because of the adverse impact of the 
disorder on cardiovascular and cerebrovascular events and target organ damage. 
Adrenalectomy potentially cures patients with unilateral PA resulting in normalisation of 
blood pressure or significant clinical improvements in the majority of patients. Different 
criteria have been used to evaluate outcomes of unilateral adrenalectomy. Clinical remission 
(cure of hypertension) is observed in 6% to 86% of patients and clinical benefits from surgery 
are seen in the majority. Several factors have been identified that predict clinical success after 
surgery such as age, sex, anti-hypertensive medication dosage and known duration of 
hypertension. Biochemical remission of PA after unilateral adrenalectomy, characterised by 
the resolution of hyperaldosteronism and correction of pre-surgical hypokalaemia, is observed 
in 67% to 100% of patients with unilateral PA. In only a small proportion of patients, 
adrenalectomy fails to resolve hyperaldosteronism and inappropriate aldosterone production 
persists after surgery. In this review we discuss the potential reasons for failing to cure 
hyperaldosteronism after unilateral adrenalectomy for unilateral primary aldosteronism. 
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Introduction 
Primary aldosteronism (PA) is a heterogeneous syndrome characterized by hypertension, 
aldosterone overproduction and suppressed plasma renin [1]. Spontaneous hypokalaemia was 
originally regarded as a critical feature, but it is now known that most patients with PA are 
normokalaemic (63-91%) [2]. The prevalence of PA is estimated as 6% in the general 
population with hypertension [1], 11% in patients referred to hypertension centres [3], and 15-
20% in patients with resistant hypertension [4]. PA is now recognised as the most frequent 
form of endocrine hypertension with unilateral PA the most common surgically curable form 
of hypertension.  
 
Patients with PA display an elevated risk of cardiovascular and cerebrovascular diseases, 
target organ damage to the heart and kidney and metabolic alterations, including metabolic 
syndrome and diabetes [5-9], compared with patients with primary hypertension with 
matched cardiovascular risk profiles [10]. These detrimental effects are caused by the 
excessive secretion of aldosterone and a potential role for glucocorticoid overproduction has 
also been reported [8,11]. PA is also associated with psychological symptoms such as anxiety 
and depression with a negative impact on quality of life [12,13]. Therefore, an early diagnosis 
and specific treatment of unilateral and bilateral PA is essential. 
 
The diagnostic work-up of PA is recommended by the Endocrine Society’s Clinical Guideline 
and begins with the screening for inappropriately elevated aldosterone production relative to 
suppressed plasma renin levels (aldosterone-to-renin ratio, ARR) in most patients with 
hypertension except those with mild hypertension [14]. Patients with a positive ARR test 
proceed to confirmation testing (including oral sodium loading, saline infusion, 
fludrocortisone suppression, and captopril challenge) and finally subtype differentiation of 
unilateral from bilateral PA (including adrenal venous sampling (AVS) and computed 
tomography (CT) scanning) [15]. The clinical management of PA depends on subtype 
differentiation: mineralocorticoid receptor (MR) antagonists for patients with bilateral PA, 
and unilateral adrenalectomy for patients with unilateral forms (including unilateral 
aldosterone producing adenomas (APA) and unilateral adrenal hyperplasia) [15]. 
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Laparoscopic adrenalectomy is the recommended surgical treatment option due to the 
associated low morbidity (5-14%), mortality well below 1% and short hospital stays of 
usually 3 days [16]. Surgical resection of the hyperfunctioning adrenal potentially normalises 
blood pressure (BP) and should reverse the detrimental effects of hormonal excess [13,16-18]. 
Clinical improvements, with significant post-surgical reductions in blood pressure, are 
observed in most patients such that a clinical benefit (complete clinical success [clinical 
remission] or partial clinical success [clinical improvement]) is achievable in over 4 out of 
every 5 patients [18]. Reasons contributing to the absence of clinical remission include the 
presence of background primary hypertension, long-standing hypertension, older age, renal 
insufficiency or other co-morbidities [19-24]. In contrast, biochemical remission with cure of 
hyperaldosteronism and normalisation of spontaneous hypokalaemia (if present pre-
surgically) should be achieved in all patients with a correct diagnosis of unilateral PA and 
surgically successful total adrenalectomy. Despite this, in a recent multicentre international 
cohort study, persistent biochemical aldosteronism after adrenalectomy was observed in 6% 
of 699 patients with a diagnosis of unilateral PA by AVS [18]. In this manuscript, we review 
outcomes after adrenalectomy and possible reasons for incomplete biochemical remission 
after total adrenalectomy, summarised in Table 1. 
 
 
Surgical and medical management of PA 
Adrenalectomy has a low frequency of major complications (1.3%) [25] and is associated 
with a high proportion of patients achieving biochemical remission [16,18,26-28]. Several 
studies report significant improvements in quality of life in patients treated surgically rather 
than medically [29-31]. Patients with medical management have worse quality of life scores 
(measured by Medical Outcomes Study Short Form 36 General Health Survey) with increased 
depression and anxiety compared with patients with surgical treatment [29,30,32]. A 
prospective study identified increased beneficial effects of surgical treatment compared with 
medical management on patient quality of life, with a health-related quality of life almost 
comparable with that of the general population [31]. This may be related to continued 
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hormone excess in patients with medical treatment which may still affect mood-regulating 
areas of the brain, and cortisol co-secretion from an APA may impair psychological well-
being [33]. 
 
A study that compared ten-year follow-up between 602 patients initiated on MR antagonists 
and 41,853 age-matched patients with primary hypertension demonstrated doubling the 
incidence of cardiovascular events in patients with PA treated with MR antagonists, despite 
comparable blood pressure levels [34]. The risks of incident diabetes, atrial fibrillation, and 
mortality were also increased in patients with MR antagonist treatment. The adverse 
cardiometabolic outcomes of patients with PA treated with MR antagonists was limited to 
patients with sustained renin activity suppression (<1 µg/L/h), therefore the study highlighted 
the importance of optimal titration of MR antagonist dosage and long-term follow-up with 
monitoring of biochemical parameters [34]. The comparison of kidney function between 
surgically and medically treated patients with PA reported a decrease in GFR and albumin 
excretion with surgical treatment compared with medical treatment with low-dose 
spironolactone (50 mg/day) [35,36]. Moreover, a large prospective study that assessed long-
term cardiovascular outcomes and mortality with a median of 11.8 years follow-up reported a 
higher potential of atrial fibrillation and lower atrial fibrillation-free survival in medically 
treated patients [37]. In contrast, the long-term outcomes of surgically treated patients were 
similar to those of patients with primary hypertension [37].  
 
Post-operative outcomes of adrenalectomy for unilateral PA 
Surgical management of unilateral PA resolves the biochemical abnormalities such as 
elevated aldosterone production, abnormal ARR and hypokalaemia (if present pre-surgically) 
in 67%-100% of patients [16,18,26-28,38]. For clinical outcomes, the proportion of patients 
achieving cure of elevated blood pressure is highly variable, ranging from 6% to 86%, with an 
improvement reported in 14%-85% of patients [13,16,18,26-28,38]. A decrease in systolic BP 
of 25 to 40 mmHg and a reduction in antihypertensive medication dosage (1-2 drug classes) 
have been reported after adrenalectomy for unilateral PA [38,39]. A reduction in left 
ventricular hypertrophy has also been reported at short-term and long-term follow-up [40]. 
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Glomerular hyperfiltration (an increased glomerular filtration rate (GFR) and decreased 
urinary albumin excretion) is reversible by surgery [35,41,42] (Table 2).  
 
The above studies used diverse diagnostic procedures, different criteria and duration of 
follow-up to assess post-surgical outcomes. The PASO (primary aldosteronism surgical 
outcome) study [18] established a set of internationally standardised criteria for outcome 
assessment in which outcomes were defined as complete (cure or remission), partial 
(improvement) and absent (failure) clinical or biochemical success with outcome assessment 
at 6-12 months. These criteria were then used to assess outcomes in an international 
multicentre cohort of 705 patients with subtype diagnosis by AVS. Biochemical remission 
classified as normalisation of plasma potassium (if hypokalaemia was present pre-surgery) 
and of the ARR was achieved in 94% of patients, with the remaining patients comprising 
those with partial biochemical success (4%) and those with absent success (2%). In contrast, 
the proportion of patients with complete clinical success (cure of hypertension) was 37%, 
with 47% of patients attaining significant clinical improvements. Female sex and younger age 
were associated with clinical benefit (complete + partial clinical success) with sex and age 
contributing to the diverse between-centre clinical outcomes. Miller et al., evaluated the 
PASO standards against other outcome criteria and reported an improvement in the definition 
of short- and long-term post-surgical outcomes with the PASO consensus [28]. 
 
Post-surgical persistent hyperaldosteronism: differentiation of unilateral from bilateral 
PA by adrenal CT scanning  
1) Subtype differentiation by adrenal CT scanning 
The successful treatment by adrenalectomy is dependent on the accurate differentiation of 
unilateral from bilateral PA. The most widely diffuse approach for subtype determination is 
CT or magnetic resonance imaging (MRI) of the adrenals to detect morphological alterations 
followed by AVS in centres where it is available. The Endocrine Society’s Clinical Guideline 
recommends adrenal CT on all patients with confirmed PA [14] to exclude adrenal 
carcinomas that are usually >40 mm in diameter and differ in densitometry from adenomas 
[43,44]. CT scanning also helps delineate the anatomy of adrenal veins to aid positioning of 
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catheters in AVS. However, the sensitivity of CT is often inadequate for detection of micro-
APAs <10 mm in diameter, and an APA can display like small hypodense (normally lower 
than 10 HU) nodules on unenhanced CT due to its high component of intracellular lipid 
[14,44]. Therefore, small APAs can be undetectable on CT, or can be misinterpreted by 
radiologists as idiopathic hyperaldosteronism when coincidently detecting bilateral nodularity 
or normal-appearing adrenals [14]. Moreover, CT cannot provide functional information on 
aldosterone secretion. Non-functioning adenomas (or incidentalomas) share a similar 
morphology to APA on CT and are difficult to differentiate, which is a problem compounded 
in older individuals >35 years old who more frequently have incidentalomas [45]. Thus, 
inappropriate adrenalectomy of a functionally normal adrenal can occur if solely relying on 
CT scanning.  
 
2) Performance of adrenal CT scanning compared with AVS 
A number of studies have compared adrenal imaging with AVS for the accuracy of 
lateralisation with some studies assessing the histology of the resected adrenal. Gordon RD et 
al., [46] reported correct CT lateralisation in around half (59/111) of patients and <25% in 
patients with an APA <10 mm in diameter, and a report from the Mayo Clinic showed that 
unnecessary adrenalectomies could occur in 25% of patients whilst 22% of patients could 
miss the chance of surgery [17]. In a systematic review, the proportion of patients with a 
misdiagnosis of PA subtypes was approximately 40% when relying on CT and MRI alone by 
comparison with AVS results as the reference standard [47]. A study comparing imaging and 
AVS results in 263 patients revealed that adrenal imaging and AVS were concordant to the 
surgically documented side in 58.6% and 97.1% of patients, respectively [27]. Another study 
included 175 patients who underwent unilateral adrenalectomy reported the accuracy of CT as 
57.3% for detecting unilateral PA, with 12.2% of contralateral (non-dominant) side of 
lateralisation and 22% of false diagnosis of bilateral PA, while AVS results could prove 
unilateral aldosterone hypersecretion correctly [48]. A recent study compared AVS with CT 
data in patients with unilateral PA (diagnosed by AVS) and biochemical cure at follow-up 
and indicated that imaging and AVS results were concordant in 64% of 491 patients with 34% 
of patients showing bilateral normal or bilateral abnormal results by CT scanning and 2% of 
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patients with unilateral abnormal imaging of the contralateral adrenal [49]. All these studies 
therefore indicated the superior performance of AVS to CT and MRI techniques for subtype 
differentiation of PA. However, a restricted subgroup of patients can bypass AVS using 
predictors of younger age and marked phenotype of PA [14]. A high accuracy (100%) of CT 
scanning has been demonstrated for lateralisation in PA with a large nodule >10 mm in 
diameter with normal appearance of the contralateral gland in young patients (aged <35 years) 
with spontaneous hypokalaemia and marked aldosterone excess at baseline [49,50]. A high 
accuracy (87%) was also noted in patients aged 35-40 years with evident symptoms [50]. 
Therefore, with the exception of young patients with a specific phenotype, most retrospective 
studies indicate that CT imaging is not as reliable as AVS for accurate subtype differentiation 
in PA.  
 
A recent randomized prospective trial compared the treatment outcomes in patients with CT- 
and AVS-based management and challenged the reference standard status of AVS [51]. A 
total of 184 patients with florid PA were randomly assigned to CT-based and AVS-based 
treatments and outcomes were assessed at one year of follow-up. The study reported no 
differences in antihypertensive medication dosage (median 3.0 vs 3.0), normalisation of target 
blood pressure (42% vs 45%), and medians of RAND-36 physical or mental score (52.7 vs 
53.2) between two groups and concluded that CT or AVS management did not result in 
significant differences in clinical benefits after one-year follow-up. Biochemical remission 
was 80% with CT-based management (vs 89% in AVS-based management) [51]. Similar 
conclusions were also made by a retrospective study that reported comparable follow-up 
blood pressures in 109 patients with CT-based and 59 patients with AVS-based 
adrenalectomy [52]. The prospective clinical trial was criticised for being underpowered with 
a non-representative study cohort due to inclusion of fewer females and florid PA that can 
predict persistence of high blood pressure due to target organ damage. The use of cosyntropin 
in the AVS procedure was also criticised because this can confound or even invert 
lateralisation thereby indicating adrenalectomy on the wrong side [53]. A retrospective 
assessment of the post-surgical outcomes of 761 patients treated by unilateral adrenalectomy 
for unilateral PA (235 and 526 patients with a surgical approach based on CT or AVS, 
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respectively) in accordance with the PASO criteria reported that CT-based surgical 
management was a predictor of a decreased likelihood of complete biochemical success, and 
was associated with inappropriate post-surgical aldosterone production and absent clinical 
success [49].  
 
Post-surgical persistent hyperaldosteronism: differentiation of unilateral from bilateral 
PA by adrenal venous sampling 
1) Influence of AVS protocol: unstimulated versus ACTH stimulated AVS 
Adrenocorticotropic hormone (ACTH) levels fluctuate in a diurnal pattern and increase when 
the hypothalamic-pituitary-adrenal axis is activated by emotional and pain-related stress 
thereby affecting both aldosterone and cortisol secretion. AVS can employ ACTH (1-24) 
(cosyntropin, a synthetic derivative of ACTH that contains the first 24 amino acids but 
maintains full function) stimulation by either constant cosyntropin infusion (50 µg/h, started 
30 min before AVS) or by bolus (usually 0.25 mg) [54].  
 
ACTH-stimulated AVS enhances the selectivity index (SI, ratio of concentrations of cortisol 
from an adrenal vein and a peripheral vein) by maximising the cortisol gradients between 
adrenal and peripheral veins, thereby increasing success rates of sampling which especially 
benefits less experienced radiologists [55]. Because ACTH minimizes cortisol fluctuations, 
AVS with sequential catheterisation can be performed [55]. Furthermore, additional cortisol 
secretion provides steroid prophylaxis for patients with high risks of allergic reaction. By 
contrast, unstimulated AVS requires additional patient management. Without cosyntropin 
stimulation, patients are suggested to be sustained in the supine position for one hour before 
AVS which should be performed in the early morning when the ACTH secretion is highest to 
avoid false-negative results [56]. Besides, measures solving emotion- and pain-related stress 
should be adopted such as reassurance from doctors, administration of benzodiazepines and 
local anesthesia [55,57]. Unstimulated AVS should also require bilateral simultaneous 
catheterisation [58]. 
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Studies that compared unstimulated with ACTH-stimulated AVS highlighted the potential 
pitfalls introduced by ACTH stimulation. It not only increases aldosterone production from 
APAs, but will also stimulate aldosterone secretion from the contralateral adrenal, thereby 
potentially reducing the lateralisation index (LI, aldosterone concentrations divided by the 
respective cortisol concentrations between adrenal veins) and introducing the possibility of a 
false diagnosis of bilateral PA [58]. A multicentre study that compared basal and ACTH 
stimulated AVS (by ACTH infusion or bolus) reported a significant increase in SI especially 
after ACTH bolus but no differences in LI between the two approaches. The discordant 
diagnoses between basal and post-ACTH conditions ranged from 17% to 36% depending on 
the criteria, with the more stringent criteria contributing to the higher reproducibility of 
diagnosis [59]. Another study with 171 patients with AVS performed before and after ACTH 
bolus found a discordance in subtype diagnosis of 28%, most of which were lateralized cases 
under basal conditions that were diagnosed as bilateral after ACTH stimulation [60]. A higher 
rate (91%) of concordant diagnoses was obtained by Wolley et al. [61], in which one 
unilateral case was diagnosed as bilateral and two bilateral cases became unilateral after 
ACTH stimulation.  
 
Hence, ACTH-stimulated AVS is useful to reduce non-diagnostic cases, allows sequential 
catheterisation, and benefits patients with an allergic reaction or when AVS cannot be 
performed in the morning. However, there is a potential to confound lateralisation results and 
therefore the protocol requires the optimization of diagnostic criteria.  
 
2) Influence of AVS protocol: simultaneous unstimulated versus sequential unstimulated 
AVS 
Oscillations of aldosterone and cortisol secretion can produce artificial gradients between 
adrenal glands if AVS is performed sequentially under basal conditions. This is circumvented 
by simultaneous cannulation but the possibility of adrenal vein thrombosis is increased 
because the procedure requires obstruction of vessel lumen by the catheter until achieving 
successful cannulation of the contralateral vein. Consequently simultaneous bilateral AVS is 
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more invasive and technically demanding and there is an inverse correlation of the rate of 
complications and the number of AVS performed by radiologists [62]. 
 
A study investigating the effect of stress on SI alterations during sequential and simultaneous 
AVS demonstrated that the SI from sequential AVS is higher than with simultaneous AVS, 
indicating differences of selectivity between the two methods of cannulation [63]. However, 
in the PASO study, the Brisbane group used a sequential unstimulated AVS approach with no 
absent biochemical success cases, which argues against important fluctuations of 
lateralisation of gradients due to stress or pulsatile secretion [18]. Moreover, a retrospective 
study compared simultaneous and sequential unstimulated AVS in 188 patients. Bilateral 
simultaneous AVS were obtained twice within five minutes, whilst sequential AVS was 
performed with a time-gap of 5 minutes between the two catheterisations. No significant 
difference was recorded in terms of the SI and LI values between simultaneous and sequential 
AVS and between two repeated simultaneous AVS. It suggested no superiority of 
simultaneous over sequential AVS under basal conditions if catheterisation of two adrenal 
veins can be achieved within five minutes [64]. 
 
Therefore, there is no consensus on the better performance of simultaneous or sequential 
unstimulated AVS, but the two approaches have a similar accuracy when performed by 
skilled and experienced radiologists if the sequential approach is performed in a short time 
interval. However, simultaneous unstimulated AVS is more likely to be preferred, considering 
potential fluctuations of aldosterone and cortisol during sequential catheterisation in an 
unstimulated AVS procedure. 
 
3) Interpretation of AVS results 
AVS results are interpreted by calculating several indexes based on aldosterone and cortisol 
concentrations in the adrenal or peripheral veins, and the cut-offs employed define the 
diagnosis. 
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SI is used to confirm adequate cannulation of adrenal veins on the assumption that cortisol is 
exclusively produced from adrenals and is not overproduced by an APA. No consensus has 
been reached on the criteria for successful catheterisation. The cut-offs of the SI vary among 
referral centres, ranging from 1.1 to 3 under basal conditions and 2 to 5 with ACTH 
stimulated AVS [65]. Expert recommendations for SI cut-offs have been proposed as ≥2 for 
unstimulated AVS, and ≥3.0 for AVS with ACTH stimulation [55], and >3 under basal 
conditions and >5 in ACTH stimulated AVS [54]. Most centres adopt SI >2 to 3 in basal 
conditions and >3 to 5 with ACTH stimulation [66], and considerable disparities in diagnosis 
are reached using less stringent criteria for successful cannulation. A study compared the 
influences of permissive (SI ≥1.1), intermediate (SI ≥2) and strict (SI ≥3) criteria on subtype 
diagnosis in unstimulated AVS. Permissive criteria achieved the highest success rate of 
bilateral cannulation (91%), while the proportion of concordant diagnoses was decreased to 
35% between the first and second AVS. It was proposed that an SI cut-off of ≥2.75 is 
necessary for diagnostic reproducibility [67]. These three criteria were compared again under 
basal AVS. It showed that the permissive cut-off values were associated with the lowest 
specificity (76.9%) and highest sensitivity (98.5%) for selectivity, whilst the strict criteria 
guaranteed 100% specificity but compromised sensitivity (50.4%). A SI cut-off of 2 was 
finally recommended by this study to gain best sensitivity (70.8%) and 100% specificity [68]. 
To identity the most accurate criteria for AVS, a study analysed 10 reported AVS criteria 
from the literature in a cohort of 108 patients with PA. An SI >5 was the most accurate with 
88% true positives and an SI >1.1 was accurate without ACTH stimulation [65]. Thus, a 
lower SI chosen for selective cannulation can increase the proportion of patients referred to 
lateralisation, but potentially compromise diagnostic accuracy with an impact on biochemical 
outcomes after adrenalectomy. 
 
The assessment of lateralization of aldosterone hypersecretion depends on the LI. Inclusion of 
cortisol concentrations from adrenal veins aims to correct for the level of adrenal aldosterone 
in case inevitable dilution by non-adrenal blood affects their concentrations. The cut-off 
values for the LI used in referral centres vary widely. Most units use an LI ≥4 for the 
diagnosis of unilateral PA, though some centres accept more permissive criteria (LI ≥3 or LI 
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≥2). More restrictive LI thresholds lead to lower rates of diagnosis of unilateral PA [67], but 
is more likely to select a population to be cured with adrenalectomy [55]. An LI cut-offs of 4 
and 2 has been recommended for ACTH-stimulated AVS and unstimulated AVS respectively 
[55]. An LI ≥4 with ACTH stimulation was recommended by another report which 
considered LI <3 to be diagnostic of BAH with 3-4 a grey zone [54]. The importance of using 
stringent LI was later highlighted by a study investigating LI from patients with hypertension 
with PA excluded. Lateralization gradients between 2 and 4 were found in 20% of patients 
with negative confirmatory test for PA, with LIs ranging from 1.01 to 3.87 [69].  
 
Additional indexes are used in some units to replace or strengthen LI results for lateralisation. 
The utility of the ipsilateral ratio (ILR), the ratio between the aldosterone/cortisol level on the 
dominant side and that level in peripheral vein, together with contralateral ratio (CLR), the 
ratio between the aldosterone/cortisol level in contralateral adrenal vein and that level in 
peripheral vein, were investigated. ILR >2 and CLR <1 were regarded by some centres as a 
useful criterion for unilateral PA [70]. Other studies displayed a lack of effect of contralateral 
aldosterone suppression on outcomes of surgically treated patients with PA [71,72]. Absolute 
contralateral aldosterone ratio that is aldosterone concentration in the contralateral adrenal 
vein divided by that in peripheral vein were set with a cut-off of 1.5 to predict outcomes after 
adrenalectomy [60]. Another use of aldosterone concentration is the absolute aldosterone 
concentration that indicates the hyperfunctioning side with aldosterone >38780 pmol/L [73]. 
All these indexes are less utilized, but they can influence the cure rate after adrenalectomy in 
centres using and interpreting them. 
 
4) Can AVS fail if it has been appropriately performed and interpreted?  
AVS is however not perfect. Bilateral PA with asymmetrical production of aldosterone will 
potentially present an AVS result of unilateral PA when the LI exceeds the stringent cut-off of 
4. AVS can also give misleading results when patients with PA have concurrent subclinical 
Cushing’s syndrome because the SI would indicate unsuccessful cannulation [74]. Patients 
with a successful AVS with a stringent LI (ranging from 4.4 to 10.0) still result in absent 
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biochemical outcomes in some cases [18]. Thus, AVS cannot guarantee success even if it has 
been appropriately performed and interpreted. 
 
Conclusions and perspectives 
Some patients with unilateral PA are not cured of persistent hyperaldosteronism after 
unilateral adrenalectomy. Focus should therefore be placed on minimizing such failures, 
which can be derived from inaccurate differentiation of unilateral from bilateral PA by either 
CT scanning or AVS. Future approaches to lateralise aldosterone production may replace or 
be used in conjunction with traditional methods and may minimise post-surgical biochemical 
persistence. Functional molecular imaging approaches using the CXCR4 ligand 68Ga-
pentixafor may visualise the hypersecreting adrenal [75] as well as other functional imaging 
methods such as 11C-metomidate positron emission tomography-CT imaging and (6β-131I) 
iodomethyl-19-norcholesterol scan [14]. Other approaches include potentially reducing the 
numbers of patients that undergo AVS by selecting patients with an APA by mass 
spectrometry-based peripheral venous steroid profiling [76,77] or using macrolide antibiotics 
that selectively inhibit aldosterone hypersecretion from APAs carrying KCNJ5 mutations [78-
80].[40,81-85] 
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TABLE LEGENDS: 
 
Table 1 Potential reasons for failing to cure hyperaldosteronism after adrenalectomy for 
unilateral PA are shown. These include adrenalectomy on the wrong side resulting from 
limitations of CT scanning (lack of sensitivity and functional information) and AVS 
(influence of protocol and interpretation of results) or adrenalectomy of ipsilateral adrenal in 
patients with bilateral PA with asymmetrical production of aldosterone. 
 
Table 2 The incidence of cardiometabolic events and target organ damage are shown for 
patients with unilateral PA compared with patients with essential hypertension at diagnosis 
and follow-up after adrenalectomy. The cardiometabolic events and target organ damage 
include stroke and/or transient ischaemic attack, coronary artery disease, arrhythmias, heat 
failure, left ventricular hypertrophy, peripheral arterial disease, metabolic syndrome, diabetes, 
and microalbuminuria.  
 
  
 
 
 
 
 
 
 
 
 
Table 1 Treatment of unilateral PA by adrenalectomy: potential reasons for incomplete 
biochemical cure 
Adrenalectomy of 
non-dominant 
(contralateral) 
adrenal 
Subtype differentiation by CT scanning:  
1) lacks sensitivity to detect micro-APAs <10 mm in diameter  
2) lack of functional information can result in resection of 
incidentaloma instead of source of aldosterone production 
Subtype differentiation by AVS: 
1) influence of protocol:  
    − sequential unstimulated AVS could result in artificial  
       gradients between adrenal glands in prolonged procedures 
2) interpretation of results:  
    − less strigent criteria for SI and LI can compromise  
       diagnostic accuracy 
Adrenalectomy of 
dominant 
(ipsilateral) 
adrenal 
Bilateral PA with asymmetrical production of aldosterone can 
potentially give an AVS result of unilateral PA. 
 
APA, aldosterone-producing adenoma; ACTH, adrenocorticotropic hormone; AVS, 
adrenal venous sampling; CT, computed tomography; LI, lateralisation index; PA, 
primary aldosteronism; SI, selectivity index. 
 
Table 2 Cardiometabolic events and target organ damage in unilateral PA versus essential hypertension at diagnosis and 
follow-up after unilateral adrenalectomy. 
Cardiometabolic 
Events and 
Target Organ 
Damage 
Diagnosis FU 
FU 
Interval 
Reference Unilateral 
PA 
EH 
Unilateral 
PA 
EH 
Stroke and/or TIA 
24/224 (11%) 12/224 (5%)    [81] 
3/29 (10%) 9/323 (3%)    [9] 
7/57 (12%) 5/171 (3%) 3/57 (5%) 2/171 (1%) 12 y [5] 
0/41 (0%) 0/894 (0%) 1/34 (3%) 7/700 (1%) 11.8 y [37] 
CAD 
(MI and/or 
Reversible 
Ischemia) 
4/224 (2%) 9/224 (4%)    [81] 
6/29 (21%) 27/323 (8%)    [9] 
3/57 (5%) 4/171 (2%) 1/57 (2%) 3/171 (2%) 12 y [5] 
0/41 (0%) 0/894 (0%) 1/34 (3%) 26/684 (4%) 11.8 y [37] 
Arrhythmias 
5/29 (17%) 11/323 (3%)    [81] 
5/57 (9%) 1/171 (0.6%) 1/57 (2%) 3/171 (2%) 12 y [5] 
2/41 (5%) 2/894 (0.2%) 2/35 (6%) 20/667 (3%) 11.8 y [37] 
Heart Failure 
8/224 (4%) 9/224 (4%)    [81] 
1/57 (2%) 1/171 (0.6%) 2/57 (4%) 0/171 (0%) 12 y [5] 
0/41 (0%) 0/894 (0%) 2/35 (6%) 10/667 (2%) 11.8 y [37] 
LVH 
9/24 (38%) 24/108 (22%) 2/24 (8%) 9/108 (8%) 6.4 y [82] 
67/110 (61%) 76/143 (53%) 50/110 (46%) 61/143 (43%) 3 y [40] 
17/26 (65%) 390/1229 (32%)    [1] 
PAD 2/29 (7%) 8/323 (2%)    [9] 
Metabolic 
Syndrome 
11/37 (30%) 39/192 (20%)    [83] 
6/9 (67%) 4/11 (36%) 5/9 (56%) NA 6 m [84] 
12/27 (44%) 441/1478 (30%)    [1] 
Diabetes 
11/50 (22%) 20/90 (22%)    [85] 
0/27 (0%) 55/1414 (4%)    [1] 
Microalbuminuria 6/21 (29%) 150/1168 (13%)    [1] 
 
CAD, coronary artery disease; EH, essential hypertension; FU, follow-up; LVH, left ventricular hypertrophy; m, months; 
MI, myocardial infarction; NA, not available; PA, primary aldosteronism; PAD, peripheral arterial disease; TIA, transient 
ischaemic attack; y, years. Values indicate numbers of patients with cardiometabolic events or target organ damage divided 
by total number of patients with the proportion of affected patients in parenthesis. 
 
